Vitrolife (VITR) Stock Overview
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VITR from our risk checks.
VITR Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 106.80 |
| 52 Week High | SEK 160.70 |
| 52 Week Low | SEK 84.60 |
| Beta | 1.72 |
| 1 Month Change | -7.93% |
| 3 Month Change | 18.80% |
| 1 Year Change | -27.84% |
| 3 Year Change | -51.45% |
| 5 Year Change | -68.02% |
| Change since IPO | 1,404.23% |
Recent News & Updates
Narrative Update • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Narrative Update • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.Narrative Update • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.Recent updates
Narrative Update • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Narrative Update • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.Narrative Update • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.Narrative Update • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.Narrative Update • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).Narrative Update • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).Narrative Update • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).Narrative Update • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.Narrative Update • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).Narrative Update • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).Analysis Article • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...Narrative Update • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.Narrative Update • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.Analysis Article • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.Narrative Update • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.Analysis Article • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...Narrative Update • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.Analysis Article • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...New Narrative • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.Analysis Article • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysis Article • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...Analysis Article • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...Analysis Article • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...Analysis Article • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...Analysis Article • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...Analysis Article • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...Analysis Article • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...Analysis Article • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...Analysis Article • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Aug 25
An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr202 Current share price of...Analysis Article • Aug 03
Vitrolife (STO:VITR) Could Easily Take On More Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Shareholder Returns
| VITR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.7% | 1.0% | 3.2% |
| 1Y | -27.8% | 29.3% | 14.4% |
Return vs Industry: VITR underperformed the Swedish Biotechs industry which returned 29.3% over the past year.
Return vs Market: VITR underperformed the Swedish Market which returned 14.4% over the past year.
Price Volatility
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: VITR has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VITR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,126 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp.
Vitrolife AB (publ) Fundamentals Summary
| VITR fundamental statistics | |
|---|---|
| Market cap | SEK 14.46b |
| Earnings (TTM) | -SEK 5.01b |
| Revenue (TTM) | SEK 3.41b |
4.2x
P/S Ratio-2.9x
P/E RatioIs VITR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VITR income statement (TTM) | |
|---|---|
| Revenue | SEK 3.41b |
| Cost of Revenue | SEK 1.41b |
| Gross Profit | SEK 2.00b |
| Other Expenses | SEK 7.01b |
| Earnings | -SEK 5.01b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 16, 2026
| Earnings per share (EPS) | -37.00 |
| Gross Margin | 58.65% |
| Net Profit Margin | -147.17% |
| Debt/Equity Ratio | 18.0% |
How did VITR perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield-3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 11:10 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vitrolife AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kallum Titchmarsh | BofA Global Research |